生物活性 | |||
---|---|---|---|
描述 | Psoralidin is a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation, with anti-cancer, anti-bacterial, and anti-inflammatory properties[3]. Three breast cancer cell populations (ALDH- cells, ALDH+ cells, and commercial BSCSs) are sensitive to Psoralidin treatment (10, 15, 20, and 25 μM; 24 hours) with IC50s ranging from 18 to 21 μM; however, the MCF-12A cells were resistant to Psoralidin. Psoralidin (30 μM; 24 hours) results in a significant induction of apoptosis for ALDH- cells, ALDH+ cells, and commercial BCSCs[4]. Psoralidin decreased the viability of the liver cancer HepG2 cells and exhibited an IC50 of 9 µM. Also, Psoralidin exerted very low toxic effects on the normal AML12 hepatocytes exhibiting an IC50 of 100 µM[5]. Psoralidin treatment could reverse the caffeine-induced dysfunctions and aberrant differentiation of BMSCs (bone marrow mesenchymal stem cells) via the ER pathway[6]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.97mL 0.59mL 0.30mL |
14.87mL 2.97mL 1.49mL |
29.73mL 5.95mL 2.97mL |
参考文献 |
---|